Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460641 · ClinicalTrials.gov registry record
Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 21
- Enrollment target
NCT01460641: Completed study, sponsored by Stanford University.
NCT01460641 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01460641 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-11 |
| Est. Completion | 2018-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01460641
The ClinicalTrials.gov registry entry for NCT01460641 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01460641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01460641 about?
NCT01460641 is a clinical study titled "Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer". A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.
What is the current status of trial NCT01460641?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2011-11. Estimated completion is 2018-07.
Who is sponsoring clinical trial NCT01460641?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.